Abstract:Bladder cancer (BC) is one of the most prevalent malignancies globally. Despite recent advancements, resistance to conventional treatments such as surgery, chemotherapy, and immunotherapy remains common among BC patients. Thus, developing novel therapeutic agents or enhancing the efficacy of current treatments is essential for better management of BC. Oncolytic adenoviruses represent a promising new approach, capable of inflaming the tumor microenvironment and eliciting tumor-specific T cell responses. In this study, we aimed to understand the immune mechanisms involved in the antitumor therapeutic efficacy of oAd/IL-12/shVEGF—an oncolytic adenovirus co-expressing interleukin-12 (IL-12) and short hairpin RNA targeting vascular endothelial growth factor (shVEGF)—both in vitro and in vivo against BC. To investigate the therapeutic potential of oAd/IL-12/shVEGF in a syngeneic MB49 BC model, tumor-bearing mice were intratumorally injected with the oncolytic virus when tumors reached 70-100 mm3. Tumor volume and body weight were monitored until the end of the experiment. Mice were sacrificed when tumors reached 2000 mm3, and both tumor and spleen tissues were disaggregated for analysis. Tumor tissues were examined for proliferation marker (PCNA), adenovirus injection marker (E1A), and antitumor immune marker (CD8) using H&E and immunohistochemical analysis. To evaluate immune modulation, levels of IFN-γ, TNF-α, and IL-12 in tumor tissues and splenocytes were measured using ELISA kits. Tumor-specific immune responses were assessed by evaluating the number of IFN-γ-secreting immune cells in splenocytes via ELISPOT assay. Statistical analysis was performed using one-way ANOVA. Treatment with oAd/IL-12/shVEGF significantly suppressed tumor growth compared to PBS-treated controls. The oncolytic virus increased levels of IFN-γ, TNF-α, and IL-12 in both tumor tissues and splenocytes compared to PBS. Additionally, oAd/IL-12/shVEGF enhanced CD8+ T cell infiltration into tumor tissues and significantly reduced PCNA expression, indicating decreased tumor cell proliferation. Consistent with these findings, the number of IFN-γ-secreting immune cells was significantly higher in mice treated with oAd/IL-12/shVEGF compared to those treated with PBS. These results suggest that oAd/IL-12/shVEGF is a promising clinical cancer immunotherapeutic agent for inducing antitumor immunity in bladder cancer. Citation Format: Yunlim Kim, Bum Jin Lim, A-Rum Yoon, Chae-Ok Yun, Choung-Soo Kim. Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A058.

Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Arg-Gly-Asp (Rgd)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model

Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice.

Menstrual Blood-Derived Stem Cells As Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer

Abstract A058: Oncolytic adenovirus induces potent anti-tumor efficacy via robust activation of immune cells in bladder cancer

Activity of antibody-drug conjugates (ADCs) with radiation in preclinical bladder cancer models.

Targeted delivery of nuclear targeting probe for bladder cancer using cyclic pentapeptide c(RGDfK) and acridine orange

Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Data from Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

Magnetic‐Powered Janus Cell Robots Loaded with Oncolytic Adenovirus for Active and Targeted Virotherapy of Bladder Cancer

[Gene Expression of Tumor Cells Both in Vitro and in Vivo Enhanced by Integrin-Targeting Adenovirus Vector].

Adenovirus-mediated Transfer of P53 and P16 Inhibiting Proliferating Activity of Human Bladder Cancer Cell EJ in Vitro and in Vivo